Soluble oligomeric TCR and antigen presentation to CTL
可溶性寡聚 TCR 和抗原呈递至 CTL
基本信息
- 批准号:6745793
- 负责人:
- 金额:$ 20.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-30 至 2006-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): It is becoming increasingly evident that along with the level of cognate peptide-MHC complexes (pMHC) their distribution on the cell surface as well as association with other membrane proteins also influences the antigen presentation. We have shown that MHC class I molecules (MHC-I) are co-clustered with adhesion molecules (ICAM-1) in both membrane rafts and soluble membrane fraction and that productive engagement of these molecules leads to their additional recruitment into rafts and increased association with Scr kinases. Disruption of the raft integrity on target cells decreases potency of viral peptides presentation to CTL. We believe that productive engagement of raft-included MHC-I and ICAM-1 during CTL-target cell encounter results in a signaling that augment presentation of cognate pMHC complexes by target cells to CTL. Based on this, we are set up to investigate functional significance of molecular assemblies on target cells and CTL. We want to identify membrane and intracellular proteins involving in these assemblies and to define mechanisms of "cross-talk" between these molecules. Our efforts are supported by 5 RO1 AI52812-01 Grant from NIAID. One important aspect of the proposal has been missing thus far. Namely, it is essential to determine the level and distribution of cognate pMHC complexes on target cells. This requires a reagent that can distinguish MHC molecules loaded with a peptide of interest from other pMHC complexes. A soluble TCR analog specific for a given pMHC may serve as an elegant tool to probe the pMHC on the surface of target cells. Because of the relatively low affinity of the TCR-pMHC reaction, soluble TCR should be oligomerized to increase the avidity of the binding. We have shown that tetrameric TCR from CTL clone D3 specific for p17 Gag epitope SLYNTVATL (SL9) can specifically detect the presence of SL9-HLA-A2 complexes on target cells. However, at lower epitope density the distance between the pMHC complexes on the cell surface may be too long for the tetramer to engage all binding sites at the same time resulting in a loss of its avidity. With this in mind, we propose here to produce other forms of oligomeric D3 TCR by increasing the valency of the tetramer and/or the distance between tetramer binding sites. We will use these reagents to characterize the distribution of SL9-HLA-A2 complexes on target cells infected with recombinant Vaccinia virus carrying HIV Gag and will determine how this parameter influences sensitivity and magnitude of CTL responses. In the future, these new reagents will be used to detect HIV infected cells in samples derived from infected individuals.
描述(由申请人提供):越来越明显的是,沿着同源肽-MHC复合物(pMHC)的水平,它们在细胞表面上的分布以及与其他膜蛋白的结合也影响抗原呈递。我们已经表明,MHC I类分子(MHC-I)与粘附分子(ICAM-1)在膜筏和可溶性膜组分中共聚集,并且这些分子的生产性参与导致其额外招募到筏中并增加与Scr激酶的关联。靶细胞上筏完整性的破坏降低了病毒肽呈递给CTL的效力。我们相信,在CTL-靶细胞相遇期间,筏包括的MHC-I和ICAM-1的有效接合导致增强靶细胞向CTL呈递同源pMHC复合物的信号传导。在此基础上,我们将研究分子组装体对靶细胞和CTL的功能意义。我们希望确定膜和细胞内的蛋白质参与这些组件,并定义这些分子之间的“串扰”的机制。我们的努力得到了NIAID的5 RO 1 AI 52812 -01赠款的支持。到目前为止,该提案的一个重要方面还没有得到重视。也就是说,必须确定靶细胞上同源pMHC复合物的水平和分布。这需要一种试剂,该试剂可以将负载有感兴趣的肽的MHC分子与其他pMHC复合物区分开。特异于给定pMHC的可溶性TCR类似物可以用作探测靶细胞表面上的pMHC的优雅工具。由于TCR-pMHC反应的亲和力相对较低,可溶性TCR应寡聚化以增加结合的亲合力。我们已经表明,来自CTL克隆D3的对p17 Gag表位SLYNTVATL(SL 9)特异性的四聚体TCR可以特异性地检测靶细胞上SL 9-HLA-A2复合物的存在。然而,在较低的表位密度下,细胞表面上的pMHC复合物之间的距离对于四聚体来说可能太长而不能同时接合所有结合位点,导致其亲合力的损失。考虑到这一点,我们在此提出通过增加四聚体的化合价和/或四聚体结合位点之间的距离来产生其他形式的寡聚D3 TCR。我们将使用这些试剂来表征SL 9-HLA-A2复合物在用携带HIV Gag的重组牛痘病毒感染的靶细胞上的分布,并将确定该参数如何影响CTL应答的灵敏度和幅度。未来,这些新试剂将用于检测来自受感染个体的样本中的HIV感染细胞。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yuri Sykulev其他文献
Yuri Sykulev的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yuri Sykulev', 18)}}的其他基金
Exploiting an artificial APC to induce different T cell subsets
利用人工 APC 诱导不同的 T 细胞亚群
- 批准号:
8893693 - 财政年份:2015
- 资助金额:
$ 20.99万 - 项目类别:
Exploiting an artificial APC to induce different T cell subsets
利用人工 APC 诱导不同的 T 细胞亚群
- 批准号:
8991045 - 财政年份:2015
- 资助金额:
$ 20.99万 - 项目类别:
Proximity between immune receptors on the cell surface and the sensitivity of Tce
细胞表面免疫受体的接近程度和 Tce 的敏感性
- 批准号:
7807106 - 财政年份:2009
- 资助金额:
$ 20.99万 - 项目类别:
Proximity between immune receptors on the cell surface and the sensitivity of Tce
细胞表面免疫受体的接近程度和 Tce 的敏感性
- 批准号:
7659807 - 财政年份:2009
- 资助金额:
$ 20.99万 - 项目类别:
JEFFERSON SHARED BIACORE INSTRUMENTATION: CANCER
Jefferson 分享 BIACORE 仪器:癌症
- 批准号:
6973320 - 财政年份:2004
- 资助金额:
$ 20.99万 - 项目类别:
Jefferson Shared Biacore Instrumentation
Jefferson 共享 Biacore 仪器
- 批准号:
6731004 - 财政年份:2004
- 资助金额:
$ 20.99万 - 项目类别:
JEFFERSON SHARED BIACORE INSTRUMENTATION: AIDS
Jefferson 共享 BIACORE 仪器:艾滋病
- 批准号:
6973319 - 财政年份:2004
- 资助金额:
$ 20.99万 - 项目类别:
Soluble oligomeric TCR and antigen presentation to CTL
可溶性寡聚 TCR 和抗原呈递至 CTL
- 批准号:
6952766 - 财政年份:2004
- 资助金额:
$ 20.99万 - 项目类别:
JEFFERSON SHARED BIACORE INSTRUMENTATION: GENETICS
Jefferson 共享 BIACORE 仪器:遗传学
- 批准号:
6973321 - 财政年份:2004
- 资助金额:
$ 20.99万 - 项目类别:
Immune receptors on Cytotoxic Lymphocytes& Target Cell
细胞毒性淋巴细胞上的免疫受体
- 批准号:
6908215 - 财政年份:2002
- 资助金额:
$ 20.99万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 20.99万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 20.99万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 20.99万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 20.99万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 20.99万 - 项目类别: